A
OCUL icon

AlphaQuest’s Ocular Therapeutix OCUL Stock Holding History

AlphaQuest’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,460
Closed -$321K – 1404
2025
Q4 		$321K Sell
26,460
-24,143
-48% -$293K 0.02% 1156
2025
Q3 		$592K Buy
50,603
+30,407
+151% +$364K 0.04% 688
2025
Q2 		$187K Buy
20,196
+13,483
+201% +$106K 0.02% 1166
2025
Q1 		$49.2K Buy
6,713
+551
+9% +$4.24K 0.01% 1536
2024
Q4 		$52.6K Buy
+6,162
New +$60.1K 0.01% 1277

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

AlphaQuest's OCUL Position: Q1 2026 in Review

AlphaQuest sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 26,460 shares — an estimated $321K sold.

AlphaQuest first reported a position in OCUL in Q4 2024 and held it in 5 quarters. The position peaked at $592K in Q3 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • AlphaQuest reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 26,460 Ocular Therapeutix shares in Q1 2026, an estimated $321K.
  • AlphaQuest first reported a position in Ocular Therapeutix in Q4 2024 and held it in 5 quarters.
  • AlphaQuest's Ocular Therapeutix position peaked at $592K in Q3 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.